Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Mismatch Repair Proficient Colorectal Carcinoma”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)UnknownNCT05933980
What this trial is testing

Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerLiver MetastasesMSS
Sun Yat-sen University 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT05205330
What this trial is testing

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Who this might be right for
Refractory Metastatic Colorectal CancerSolid TumorMetastatic Microsatellite-stable Colorectal Cancer+3 more
Rottapharm Biotech 107
Testing effectiveness (Phase 2)WithdrawnNCT04119830
What this trial is testing

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Who this might be right for
Metastatic Colorectal AdenocarcinomaMicrosatellite StableMismatch Repair Proficient+10 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)WithdrawnNCT06730100
What this trial is testing

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Who this might be right for
Metastatic Mismatch Repair Proficient Colorectal CarcinomaRefractory Mismatch Repair Proficient Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT05733611
What this trial is testing

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Who this might be right for
Refractory Metastatic Colorectal CancerpMMRMSS
Replimune, Inc. 5
Early research (Phase 1)Study completedNCT03712943
What this trial is testing

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Who this might be right for
Colorectal CancerMetastatic Colorectal CancerColon Cancer
H. Lee Moffitt Cancer Center and Research Institute 52
Testing effectiveness (Phase 2)Looking for participantsNCT06522919
What this trial is testing

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Testing effectiveness (Phase 2)Study completedNCT03711058
What this trial is testing

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Who this might be right for
Unresectable or Metastatic Microsatellite Stable (MSS) Solid TumorMicrosatellite Stable (MSS) Colon Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 48
36